Management of Varicose Veins and Chronic Venous Insufficiency in a Comparative Registry with Nine Venoactive Products in Comparison with Stockings

Abstract

The aim of this registry study was to compare products used to control symptoms of CVI. Endpoints of the study were microcirculation, effects on volume changes, and symptoms (analogue scale). Pycnogenol, venoruton, troxerutin, the complex diosmin-hesperidin, Antistax, Mirtoselect (bilberry), escin, and the combination Venoruton-Pycnogenol (VE-PY) were compared with compressions.

No safety or tolerability problems were observed. At inclusion, measurements in the groups were comparable: 1,051 patients completed the registry. Best performers: Venoruton, Pycnogenol, and the combination VE-PY produced the best effects on skin flux. These products and the combination VE-PY better improved PO₂ and PCO₂. The edema score was decreased more effectively with the combination and with Pycnogenol. Venoruton; Antistax also had good results. Considering volumetry, the best performers were the combination PY-VE and the two single products Venoruton and Pycnogenol. Antistax results for edema were also good. The best improvement in symptoms score were obtained with Pycnogenol and compression. A larger decrease in oxidative stress was observed with Pycnogenol, Venoruton, and with the VE-PY combination. Good effects of Antistax were also observed. Parestesias were lower with Pycnogenol and with Antistax. Considering the need for interventions, the best performers were Pycnogenol, VE-PY, and compression. The efficacy of Pycnogenol and the combination are competitive with stockings that do not have the same tolerability in warmer climates. A larger and more prolonged evaluation is suggested to evaluate cost-efficacy (and non-interference with drugs) of these products in the management of CVI. The registry is in progress; other products are in evaluation.

Keywords

chronic venous insufficiency - venous disease - varicose veins - elastic stockings - venoactive compounds - edema

• References

• 1 Nicolaides AN. ; Cardiovascular Disease Educational and Research Trust; European Society of Vascular Surgery; The International Angiology Scientific Activity Congress Organization; International Union of Angiology; Union Internationale de Phlebologie at the Abbaye des Vaux de Cernay. Investigation of chronic venous insufficiency: a consensus statement (France, March 5–9, 1997). Circulation 2000; 102 (20) E126-E163
• 2 Christopoulos D, Tachtsi M, Pitoulias G, Belcaro G, Papadimitriou D. Hemodynamic follow-up of iliofemoral venous thrombosis. Int Angiol 2009; 28 (05) 394-399
• 3 Chan S, Belcaro G, Nicolaides AN. Chronic venous insufficiency. In: Haimovici H. , ed. Haimovici's Vascular Surgery. Cambridge, Mass:: Blackwell Sciences; 1242-1258
• 4 Lee BB, Nicolaides AN, Myers K. , et al. Venous hemodynamic changes in lower limb venous disease: the UIP consensus according to scientific evidence. Int Angiol 2016; 35 (03) 236-352
• 5 Esperester A, Schütt T, Ottillinger B. [Drugs in chronic venous insufficiency—the challenge of demonstrating clinical efficacy] [in German]. Med Monatsschr Pharm 2013; 36 (02) 44-51
• 6 Belcaro G, Dugall M, Luzzi R, Hosoi M, Corsi M. Improvements of venous tone with pycnogenol in chronic venous insufficiency: an ex vivo study on venous segments. Int J Angiol 2014; 23 (01) 47-52
• 7 Errichi BM, Belcaro G, Hosoi M. , et al. Prevention of post thrombotic syndrome with Pycnogenol® in a twelve month study. Panminerva Med 2011; 53 (3, Suppl 1): 21-27
• 8 Cesarone MR, Belcaro G, Rohdewald P. , et al. Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study. Phytomedicine 2010; 17 (11) 835-839
• 9 Cesarone MR, Belcaro G, Rohdewald P. , et al. Rapid relief of signs/symptoms in chronic venous microangiopathy with pycnogenol: a prospective, controlled study. Angiology 2006; 57 (05) 569-576
• 10 Belcaro G, Cesarone MR, Ricci A. , et al. Control of edema in hypertensive subjects treated with calcium antagonist (nifedipine) or angiotensin-converting enzyme inhibitors with Pycnogenol. Clin Appl Thromb Hemost 2006; 12 (04) 440-444
• 11 Cesarone MR, Belcaro G, Rohdewald P. , et al. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb Hemost 2006; 12 (02) 205-212
• 12 Vinciguerra G, Belcaro G, Cesarone MR. , et al. Cramps and muscular pain: prevention with pycnogenol in normal subjects, venous patients, athletes, claudicants and in diabetic microangiopathy. Angiology 2006; 57 (03) 331-339
• 13 Rabe E, Stücker M, Esperester A, Schäfer E, Ottillinger B. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency—results of a double-blind placebo-controlled study. Eur J Vasc Endovasc Surg 2011; 41 (04) 540-547
• 14 Butcher M. A review of evidence on red vine leaf extract in the prevention and management of venous disease. J Wound Care 2006; 15 (09) 393-396
• 15 Monsieur R, Van Snick G. [Efficacy of the red vine leaf extract AS 195 in Chronic Venous Insufficiency] [in French]. Praxis (Bern 1994) 2006; 95 (06) 187-190
• 16 Rabe E, Pannier F, Larenz B. [Red vine leaf extract (AX 195) for chronic venous insufficiency]. Med Monatsschr Pharm 2005; 28 (02) 55-59
• 17 Belcaro G, Nicolaides AN. The Venous Clinic. London, UK: Imperial College Press; 2006
• 18 Belcaro G, Nicolaides AN, Veller M. A Manual of Venous Disorders. London, UK: Saunders; 2001
• 19 Belcaro G, Nicolaides AN. Noninvasive Investigations in Vascular Disease. London, UK: Imperial College Press; 2007
• 20 Belcaro G, Hoffman U, Bollinger A, Nicolaides AN. Laser Doppler. London, UK: MedOrion; 1999
• 21 Belcaro G. Laser Doppler. PhD Thesis, University of London; 1997
• 22 Belcaro G, Cesarone MR, de Sanctis MT. , et al. Laser Doppler and transcutaneous oximetry: modern investigations to assess drug efficacy in chronic venous insufficiency. Int J Microcirc Clin Exp 1995; 15 (Suppl. 01) 45-49
• 23 Passman MA, McLafferty RB, Lentz MF. , et al. Validation of Venous Clinical Severity Score (VCSS) with other venous severity assessment tools from the American Venous Forum, National Venous Screening Program. J Vasc Surg 2011; 54 (6, Suppl): 2S-9S
• 24 Kakkos SK, Rivera MA, Matsagas MI. , et al. Validation of the new venous severity scoring system in varicose vein surgery. J Vasc Surg 2003; 38 (02) 224-228
• 25 Cesarone MR, Belcaro G, Carratelli M. , et al. A simple test to monitor oxidative stress. Int Angiol 1999; 18 (02) 127-130
• 26 Belcaro G, Cornelli U, Ledda A, Hosoi M. Assessment of nutraceuticals and food supplements. Panminerva Med 2011; 53 (3, Suppl 1): I-II
• 27 Belcaro G, Nicolaides AN. Natural drugs in vascular medicine: new observations. J Cardiovasc Pharmacol Ther 2002; 7 (Suppl. 01) S1
• 28 Belcaro G, Nicolaides AN. A new role for natural drugs in cardiovascular medicine. Angiology 2001; 52 (Suppl. 02) S1
• 29 Singh R, Wang O. Clinical trials in “emerging markets”: regulatory considerations and other factors. Contemp Clin Trials 2013; 36 (02) 711-718
• 30 Belcaro G. Pharma Standard Supplements: Clinical Use. London, UK: Imperial College Press; 2016
• 31 http://mayoresearch.mayo.edu/center-for-individualized-medicine/personalized-medicine.asp
• 32 Porter RS, Kaplan JL. , eds. The Merck Manual. 12th ed. Whitehouse Station, NJ: Merck, Sharp & Dohme Corp.; 2011
• 33 Christle JW, Schlumberger A, Haller B, Gloeckl R, Halle M, Pressler A. Individualized vs. group exercise in improving quality of life and physical activity in patients with cardiac disease and low exercise capacity: results from the DOPPELHERZ trial. Disabil Rehabil 2016; 1-6
• 34 Gulati OP. Pycnogenol® in chronic venous insufficiency and related venous disorders. Phytother Res 2014; 28 (03) 348-362
• 35 Belcaro G, Luzzi R, Dugall M. Antistax does not change the activity of antithrombotic agents in subjects with post-thrombotic syndrome. Int J Pharma Standard Suppl. Mim Mad, Turin 2016; 74-75